The shortage list was the legal mechanism that permitted 503B outsourcing facilities to compound these drugs in bulk for office use. With the shortage designation gone, the underlying legal authority for bulk 503B compounding of these two drugs is gone with it
The February 20, 2026 FDA action against 30 telehealth companies reshaped the landscape
The FDA approval of Kirsty, the first and only interchangeable biosimilar rapid-acting insulin aspart in the US, is a significant step forward in our efforts to make insulin more accessible and affordable, said Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd
Well you can take liposomal glutathione
A.WeikopP.GrahamD
246 Therefore, obesity seems to be a double-edged sword for cancer immunotherapy, and the underlying mechanisms remain unclear and require further investigation